CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), as well as cytotoxic T-lymphocyte antigen 4 (CTLA-4) have become the standard of care for many tumour types and are now indicated in approximately half of US patients with advanced or metastatic cancer [1,2].